U.K. To Leverage NHS Data As Part Of Broader Stimulus Package, But Details Still Sketchy
Executive Summary
Industry welcomed the initiatives, which included making National Health Service clinical data more widely available and strengthening NICE's role.
You may also be interested in...
U.K. Value-Based Pricing Negotiations Could Help NICE-Rejected Cancer Drugs
Negotiations will start in September 2012 on a value-based pricing approach for new medicines in the U.K., and on a new PPRS scheme for currently marketed drugs, with a new suggestion: oncologics previously rejected by NICE might be reviewed again under the new VBP system.
AZ, IMS To Build Disparate Data Sets Into Broader Outcomes Consensus
Individual deals with payers or information providers won’t provide pharma with the breadth of outcomes data they need to secure reimbursement for their drugs. A far broader stakeholder consensus is required.
AstraZeneca’s Real-World Outcomes Deal With IMS Aims To Turn Treatment Data Into Business Decisions
Accessing IMS Health’s European electronic health records and jointly building a customized data analysis platform will inform AstraZeneca’s R&D priorities and support outcomes claims of newly-launched drugs.